加蓬成人联合接种钩虫疫苗Na-GST-1与Na-APR-1的安全性和免疫原性:随机对照双盲1期剂量递增试验
在加蓬美洲钩虫流行区开展随机、对照、双盲1期剂量递增试验,32名18-50岁健康成人分入30 μg或100 μg联合疫苗组及对照组。两剂疫苗耐受良好,未记录疫苗相关严重或重度不良事件;100 μg组在第三剂后2周全部发生IgG血清阳转。
要点
- 联合接种Na-GST-1与Na-APR-1(M74)在流行区成人中安全、耐受良好。
- 100 μg剂量组第三剂后2周全部受试者发生IgG血清阳转。
- 第三剂后6个月IgG仍显著高于基线(100 μg组)。
核心结论
- 在加蓬美洲钩虫流行区健康成人中,重组Na-GST-1与Na-APR-1(M74)联合接种安全并诱导针对各抗原的IgG。
- 作者认为这是首项报告Na-APR-1(M74)与Alhydrogel联合用于美洲钩虫流行区参与者的研究。
- 后续临床开发应开展效力研究。
研究设计与样本
- 随机、对照、双盲、1期剂量递增试验,在加蓬Lambaréné的Centre de Recherches Médicales de Lambaréné开展。
- 招募18-50岁居住于Lambaréné及周边健康成人,连续入组30 μg与100 μg两个剂量队列。
- 按区组(区组大小4)随机接受三剂联合疫苗(每种抗原30 μg或100 μg,Alhydrogel加GLP类水剂佐剂)或乙肝疫苗加生理盐水对照。
- 疫苗于第0、28、180天肌内注射;主要终点为安全性,免疫原性为次要终点。
- 安全性用意向治疗人群分析,免疫原性用符合方案人群分析;两剂量队列对照合并分析;注册号NCT02126462。
主要发现
- 2014年10月27日至2015年1月31日筛查56人,32人入组随机分组:30 μg与100 μg实验疫苗组各12人,对照组8人。
- 两剂量组疫苗均耐受良好,最常见不良事件为轻至中度注射部位疼痛、头痛、肌痛和恶心。
- 未记录疫苗相关重度或严重不良事件;研究期间发生52例非 solicited 疫苗相关不良事件,疫苗组间频率无差异(原文未报告具体比较数值)。
- 各疫苗抗原均诱导IgG抗体,平均IgG水平在每次接种后升高。
- 100 μg剂量组第三剂后2周观察到两抗原IgG峰值应答且全部受试者血清阳转;至第三剂后6个月最终访视IgG逐步下降,但100 μg组仍显著高于基线。
关键数值与推荐
- 实验疫苗剂量:每种抗原30 μg或100 μg,共三剂,第0、28、180天肌内注射。
- 佐剂:Alhydrogel(氢氧化铝凝胶混悬液)联合glucopyranosyl lipid A水剂。
- 血清阳转定义:IgG水平高于反应性阈值;100 μg组第三剂后2周全部受试者阳转。
- 对照:乙肝疫苗加生理盐水。
临床怎么用
- 提示联合钩虫疫苗在流行区成人中具可接受安全性,支持进一步开展效力研究。
- 100 μg剂量免疫原性更稳定,可作为后续开发参考剂量。
- 接种后需关注注射部位疼痛、头痛、肌痛和恶心等轻中度反应。
局限性
- 为1期小样本试验(32人),主要评价安全性与免疫原性,未评估保护效力。
- 免疫原性分析采用符合方案人群,可能引入依从性相关偏倚。
- 随访至第三剂后6个月,长期免疫持久性未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hookworms cause substantial morbidity in children and women of reproductive age. The control strategy of mass drug administration is suboptimal, hence the need for a vaccine. Necator americanus aspartic protease-1 (Na-APR-1) and N americanus glutathione S-transferase-1 (Na-GST-1) are involved in the digestion and detoxification of haemoglobin in the hookworm digestive tract. In animal models, vaccination against these antigens resulted in protection from challenge infection. Both vaccine candidates were shown to be safe and well tolerated when administered separately to healthy adults. We assessed the safety and immunogenicity of co-administered Na-GST-1 and Na-APR-1 (M74) vaccines in healthy Gabonese adults. METHODS: This randomised, controlled, double-blind, phase 1, dose-escalation trial was done at the Centre de Recherches Médicales de Lambaréné, in a region of Gabon where N americanus and other helminths are prevalent. Healthy adults aged 18-50 years and living in Lambaréné or the surrounding areas were recruited to the study. Participants were enrolled consecutively into two dose cohorts (30 μg or 100 μg of the experimental vaccines) and randomly assigned in blocks (block size four) to receive three doses of either co-administered Na-GST-1 plus Na-APR-1 (M74; 30 μg or 100 μg of each), adjuvanted with Alhydrogel (aluminium hydroxide gel suspension) together with an aqueous formulation of glucopyranosyl lipid A, or hepatitis B vaccine plus saline (control group). Vaccines were administered intramuscularly on days 0, 28, and 180. The primary endpoint was safety, with immunogenicity a secondary endpoint. The intention-to-treat population was used for safety analyses, whereas for immunogenicity analyses, the per-protocol population was used (participants who received all scheduled vaccinations). Control vaccine recipients for both dose cohorts were combined for the analyses. The trial is registered with ClinicalTrials.gov, NCT02126462. FINDINGS: Between Oct 27, 2014, and Jan 31, 2015, 56 individuals were screened for eligibility, of whom 32 were enrolled and randomly assigned to one of the three study groups (12 each in the 30 μg and 100 μg experimental vaccine groups and eight in the control group). Both study vaccines were well tolerated in both dose groups. The most common adverse events were mild-to-moderate injection-site pain, headache, myalgia, and nausea. No severe or serious adverse events related to the vaccines were recorded. 52 unsolicited vaccine-related adverse events occurred during the study, but there was no difference in frequency between vaccine groups. IgG antibodies were induced to each of the vaccine antigens, with mean IgG levels increasing after each vaccination. Vaccination with 100 μg of each vaccine antigen consistently induced IgG seroconversion (IgG levels above the reactivity threshold). Peak IgG responses were observed 2 weeks after the third vaccine dose for both antigens, with all participants who received the 100 μg doses seroconverting at that timepoint. IgG levels steadily declined until the final study visit 6 months after the third vaccination, although they remained significantly higher than baseline in the 100 μg dose group. INTERPRETATION: Vaccination with recombinant Na-GST-1 and Na-APR-1 (M74) in healthy adults living in N americanus-endemic areas of Gabon was safe and induced IgG to each antigen. To our knowledge, this study is the first to report results of Na-APR-1 (M74) co-administered with Alhydrogel in participants from an N americanus-endemic area. Further clinical development of these vaccines should involve efficacy studies. FUNDING: European Union Seventh Framework Programme.
引用
- Adegnika AA, de Vries SG, Zinsou FJ, et al. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2020. PMID: 32926834. doi:10.1016/S1473-3099(20)30288-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。